Aquestive Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Aquestive Therapeutics, Inc.‘s stocks are currently a part of 40 hedge funds’ portfolios, which represents 33.16% of the total amount of its stocks outstanding. This makes up a total of 15.07M shares of Aquestive Therapeutics, Inc.. Compared to the previous quarter, the number fell by -9.88% or -1.65M shares fewer. As for the holding position changes, 17.5% (7) of current hedge fund investors increased the number of shares held, 30% (12) of current holders sold a part of the shares held, and 12.5% (5) closed the holdings completely. 8 hedge funds are new holders of Aquestive Therapeutics, Inc. stock in Q3 2022, it is 20% of total holders.
Hedge funds holding Aquestive Therapeutics (Q3 2018 – Q3 2022)
| Q3 2018 | 44 |
|---|---|
| Q4 2018 | 37 |
| Q1 2019 | 50 |
| Q2 2019 | 40 |
| Q3 2019 | 36 |
| Q4 2019 | 57 |
| Q1 2020 | 43 |
| Q2 2020 | 57 |
| Q3 2020 | 60 |
| Q4 2020 | 65 |
| Q1 2021 | 63 |
| Q2 2021 | 56 |
| Q3 2021 | 44 |
| Q4 2021 | 51 |
| Q1 2022 | 49 |
| Q2 2022 | 41 |
| Q3 2022 | 40 |
Hedge funds changes in Aquestive Therapeutics positions (Q3 2018 – Q3 2022)
| Q3 2018 | 44 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q4 2018 | 12 | 9 | 9 | 18 | -11 |
| Q1 2019 | 19 | 14 | 9 | 6 | 2 |
| Q2 2019 | 8 | 6 | 14 | 17 | -5 |
| Q3 2019 | 8 | 8 | 11 | 12 | -3 |
| Q4 2019 | 28 | 14 | 11 | 7 | -3 |
| Q1 2020 | 7 | 20 | 12 | 20 | -16 |
| Q2 2020 | 25 | 16 | 9 | 10 | -3 |
| Q3 2020 | 15 | 22 | 16 | 11 | -4 |
| Q4 2020 | 15 | 17 | 21 | 10 | 2 |
| Q1 2021 | 13 | 18 | 21 | 14 | -3 |
| Q2 2021 | 19 | 11 | 22 | 26 | -22 |
| Q3 2021 | 5 | 11 | 17 | 17 | -6 |
| Q4 2021 | 13 | 19 | 11 | 7 | 1 |
| Q1 2022 | 5 | 14 | 19 | 6 | 5 |
| Q2 2022 | 6 | 10 | 10 | 14 | 1 |
| Q3 2022 | 8 | 7 | 12 | 5 | 8 |
Hedge funds changes in Aquestive Therapeutics stock options (Q3 2018 – Q3 2022)
| Q3 2018 | 0 | 0 |
|---|---|---|
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 2,000 |
| Q2 2020 | 671,000 | 542,000 |
| Q3 2020 | 270,000 | 1,316,000 |
| Q4 2020 | 295,000 | 898,000 |
| Q1 2021 | 902,000 | 1,220,000 |
| Q2 2021 | 592,000 | 428,000 |
| Q3 2021 | 1,072,000 | 810,000 |
| Q4 2021 | 1,021,000 | 1,065,000 |
| Q1 2022 | 420,000 | 268,000 |
| Q2 2022 | 33,000 | 9,000 |
| Q3 2022 | 28,000 | 0 |